Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

885
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
885
Glaucoma: Overview01:25

Glaucoma: Overview

1.1K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.0K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.0K
The Blood-brain Barrier00:49

The Blood-brain Barrier

51.7K
Overview
51.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing research publication of nurse researchers through a mentored writing retreat programme (MWRP): A participatory action research protocol.

MethodsX·2026
Same author

The rise of bispecific antibodies for dual targeting, singular impact: technology and clinical advancements.

International immunopharmacology·2026
Same author

Multi-strain bacterial combination mitigates pelvic irradiation-induced gut damage by preserving gut integrity, inhibiting inflammation and apoptosis.

Scientific reports·2026
Same author

Synergizing immunity: lipid nanoparticle-mediated mRNA and gene delivery as a next-gen paradigm in cancer immunotherapy.

International journal of pharmaceutics·2026
Same author

Continuous Manufacturing of Controlled-Release Metoprolol Succinate Tablets by Novel Hot-Melt Fragmentation Technology.

AAPS PharmSciTech·2026
Same author

Reverse Phase High Performance Liquid Chromatography Method for the Estimation of Mangiferin in Nano Formulations: Development and Optimization by Analytical Quality-by-Design.

ACS omega·2026

Related Experiment Video

Updated: Dec 20, 2025

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

20.3K

Neuroprotection: A versatile approach to combat glaucoma.

Santoshi Naik1, Abhijeet Pandey1, Shaila A Lewis1

  • 1Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka State, India.

European Journal of Pharmacology
|May 29, 2020
PubMed
Summary

This review explores neuroprotection strategies to prevent vision loss in retinal diseases like glaucoma. It covers neurotrophic, antioxidative, and other therapies, including the role of nanoplatforms.

Keywords:
GeneticsGlaucomaNanoplatformsNeuroprotection

More Related Videos

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina
09:46

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina

Published on: July 15, 2025

1.3K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.5K

Related Experiment Videos

Last Updated: Dec 20, 2025

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

20.3K
An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina
09:46

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina

Published on: July 15, 2025

1.3K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.5K

Area of Science:

  • Ophthalmology and Neuroscience
  • Focus on retinal disease mechanisms and therapeutic interventions.

Background:

  • Neuronal loss is a primary driver of vision impairment in retinal diseases.
  • Neuroprotection aims to preserve neuronal survival and function in hostile environments.
  • Therapeutic advancements offer hope for improved patient outcomes.

Purpose of the Study:

  • To review current neuroprotection strategies for glaucoma treatment.
  • To discuss the genetics of glaucoma.
  • To examine the application of nanoplatforms in glaucoma therapy.

Main Methods:

  • Literature review of neuroprotection strategies.
  • Analysis of glaucoma genetics.
  • Evaluation of nanoplatforms in ocular disease treatment.

Main Results:

  • Neuroprotection encompasses diverse therapies: neurotrophic, antioxidative, anti-excitotoxic, anti-ischemic, anti-inflammatory, and anti-apoptotic.
  • Glaucoma involves complex genetic factors.
  • Nanoplatforms show potential for targeted drug delivery in glaucoma.

Conclusions:

  • Neuroprotection offers promising avenues for treating glaucoma and other retinal diseases.
  • Understanding glaucoma genetics is crucial for developing targeted therapies.
  • Nanotechnology presents innovative solutions for enhanced glaucoma treatment.